Inhalable insulin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inhalable insulin" in English language version.

refsWebsite

Global rank English rank

4doi.org

2^nd place

4web.archive.org

1^st place

4nih.gov

4^th place

3fda.gov

447^th place

338^th place

2semanticscholar.org

11^th place

8^th place

2fiercepharma.com

low place

8,921^st place

2mannkindcorp.com

low place

1researchgate.net

120^th place

125^th place

1cnn.com

28^th place

26^th place

1diabetes.org.uk

low place

1pqarchiver.com

490^th place

322^nd place

1bbc.co.uk

8^th place

10^th place

1bioworld.com

low place

1nytimes.com

7^th place

1fiercebiotech.com

low place

8,828^th place

1diabetesjournals.org

low place

1worldcat.org

5^th place

bbc.co.uk

news.bbc.co.uk

"Inhaled insulin given UK launch". BBC News. August 4, 2006. Retrieved July 19, 2016.

bioworld.com

"Alkermes Inc. AIR Inhaled Insulin System Human insulin inhalation powder Began Phase III trial to evaluate effectiveness in improving glucose control vs. injected premeal insulin in 400 patients 4/06 Type II diabetes". Bioworld Today. January 1, 2007. Retrieved 2007-10-22.^{[dead link]}

cnn.com

money.cnn.com

Simons J (19 October 2007). "How the Exubera debacle hurts Pfizer". CNNMoney. Retrieved 2007-10-21.

diabetes.org.uk

"100 Years of Insulin". Diabetes UK.

diabetesjournals.org

diabetes.diabetesjournals.org

Snell-Bergeon, Janet K.; Akturk, Halis K.; Rewers, Amanda; Bode, Bruce W.; Klaff, Leslie J.; Peters, Anne; Bailey, Timothy S.; Garg, Satish K. (2018-07-01). "Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study". Diabetes. 67 (Supplement 1): 1017–P. doi:10.2337/db18-1017-P. ISSN 0012-1797. S2CID 90171098.

doi.org

McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T (August 2016). "Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?". Advances in Therapy. 33 (8): 1267–78. doi:10.1007/s12325-016-0370-1. PMID 27384191. S2CID 25390720.
Oleck J, Kassam S, Goldman JD (August 2016). "Commentary: Why Was Inhaled Insulin a Failure in the Market?". Diabetes Spectrum. 29 (3): 180–4. doi:10.2337/diaspect.29.3.180. PMC 5001220. PMID 27574374.
Black C, Cummins E, Royle P, Philip S, Waugh N (September 2007). "The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation". Health Technology Assessment. 11 (33): 1–126. doi:10.3310/hta11330. PMID 17767897.
Snell-Bergeon, Janet K.; Akturk, Halis K.; Rewers, Amanda; Bode, Bruce W.; Klaff, Leslie J.; Peters, Anne; Bailey, Timothy S.; Garg, Satish K. (2018-07-01). "Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study". Diabetes. 67 (Supplement 1): 1017–P. doi:10.2337/db18-1017-P. ISSN 0012-1797. S2CID 90171098.

fda.gov

"FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes" (Press release). Silver Spring, Maryland: FDA. 2006-01-27.
"FDA approves Afrezza to treat diabetes" (News Release). U.S. Food and Drug Administration. June 27, 2014. Archived from the original on July 6, 2014. Retrieved July 19, 2016.

accessdata.fda.gov

"US Afrezza label" (PDF). FDA. May 2015.

fiercebiotech.com

Carroll J (August 11, 2014). "Sanofi fills some big shoes in $925M Afrezza pact with MannKind". FierceBiotech.

fiercepharma.com

Staton T (February 10, 2016). "Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?". FiercePharma.
Palmer, Eric (November 10, 2016). "Sanofi forgives MannKind's boatload of debt over failed Afrezza deal". FiercePharma.

mannkindcorp.com

"Technosphere Insulin - How it works". MannKind Corp. 2007. Archived from the original on 2007-10-20. Retrieved 2007-10-22.

investors.mannkindcorp.com

"MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA(R)". MannKind Corporation. January 19, 2011. Archived from the original on August 23, 2016. Retrieved July 19, 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T (August 2016). "Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?". Advances in Therapy. 33 (8): 1267–78. doi:10.1007/s12325-016-0370-1. PMID 27384191. S2CID 25390720.
Oleck J, Kassam S, Goldman JD (August 2016). "Commentary: Why Was Inhaled Insulin a Failure in the Market?". Diabetes Spectrum. 29 (3): 180–4. doi:10.2337/diaspect.29.3.180. PMC 5001220. PMID 27574374.
Black C, Cummins E, Royle P, Philip S, Waugh N (September 2007). "The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation". Health Technology Assessment. 11 (33): 1–126. doi:10.3310/hta11330. PMID 17767897.

ncbi.nlm.nih.gov

Oleck J, Kassam S, Goldman JD (August 2016). "Commentary: Why Was Inhaled Insulin a Failure in the Market?". Diabetes Spectrum. 29 (3): 180–4. doi:10.2337/diaspect.29.3.180. PMC 5001220. PMID 27574374.

nytimes.com

Pollack A (November 16, 2007). "Betting an Estate on Inhaled Insulin". The New York Times. Retrieved May 5, 2010.

pqarchiver.com

pqasb.pqarchiver.com

Gillis J (January 28, 2006). "Inhaled Form of Insulin Is Approved". The Washington Post. Archived from the original on 2018-04-29. Retrieved 2007-10-21.

researchgate.net

Neumiller, Joshua (June 2010). "Pharmacologist". Annals of Pharmacotherapy. 1231–9 (44): 7.

semanticscholar.org

api.semanticscholar.org

McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T (August 2016). "Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?". Advances in Therapy. 33 (8): 1267–78. doi:10.1007/s12325-016-0370-1. PMID 27384191. S2CID 25390720.
Snell-Bergeon, Janet K.; Akturk, Halis K.; Rewers, Amanda; Bode, Bruce W.; Klaff, Leslie J.; Peters, Anne; Bailey, Timothy S.; Garg, Satish K. (2018-07-01). "Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study". Diabetes. 67 (Supplement 1): 1017–P. doi:10.2337/db18-1017-P. ISSN 0012-1797. S2CID 90171098.

web.archive.org

"FDA approves Afrezza to treat diabetes" (News Release). U.S. Food and Drug Administration. June 27, 2014. Archived from the original on July 6, 2014. Retrieved July 19, 2016.
Gillis J (January 28, 2006). "Inhaled Form of Insulin Is Approved". The Washington Post. Archived from the original on 2018-04-29. Retrieved 2007-10-21.
"Technosphere Insulin - How it works". MannKind Corp. 2007. Archived from the original on 2007-10-20. Retrieved 2007-10-22.
"MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA(R)". MannKind Corporation. January 19, 2011. Archived from the original on August 23, 2016. Retrieved July 19, 2016.

worldcat.org

search.worldcat.org

Snell-Bergeon, Janet K.; Akturk, Halis K.; Rewers, Amanda; Bode, Bruce W.; Klaff, Leslie J.; Peters, Anne; Bailey, Timothy S.; Garg, Satish K. (2018-07-01). "Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study". Diabetes. 67 (Supplement 1): 1017–P. doi:10.2337/db18-1017-P. ISSN 0012-1797. S2CID 90171098.